Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Neuroscience

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0306-4522(91)90180-VPMID 2052148
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neurotoxic damage to the nigrostriatal system in rats following intranigral administration of MPDP+ and MPP+

  2005cited by this paper
• Quantitative autoradiography of the rat brain vesicular monoamine transporter using the binding of [3H]dihydrotetrabenazine and 7-amino-8-[125I]iodoketanserin.

  1989cited by this paper
• Hemiparkinsonism in monkeys after unilateral caudate nucleus infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior and histology.

  1988cited by this paper
• Recommended safe practices for using the neurotoxin MPTP in animal experiments.

  1988cited by this paper
• Administration of MPTP acutely increases glucose utilization in the substantia nigra of primates.

  1988cited by this paper
• Metabolism of [14C]MPTP in mouse and monkey implicates MPP+, and not bound metabolites, as the operative neurotoxin.

  1988cited by this paper
• MPTP, impairment of motor performance and amine accumulation in Macaca fascicularis.

  1987cited by this paper
• Uptake, Release, and Subcellular Localization of l‐Methyl‐4‐Phenylpyridinium in Blood Platelets

  1987cited by this paper
• Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  1986cited by this paper
• Injury of nigral neurons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a tyrosine hydroxylase immunocytochemical study in monkey.

  1986cited by this paper
• Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin.

  1986cited by this paper
• Uptake inhibition protects nigro-striatal dopamine neurons from the neurotoxicity of 1-methyl-4-phenylpyridine (MPP+) in mice.

  1986cited by this paper
• Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.

  1985cited by this paper
• Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

  1984cited by this paper
• Region‐specific distribution of catecholamine afferents in primate cerebral cortex: A fluorescence histochemical analysis

  1984cited by this paper
• N-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) causes destruction of the nigrostriatal but not the mesolimbic dopamine system in the monkey.

  1984cited by this paper
• Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism

  1984cited by this paper
• Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey.

  1984cited by this paper
• Monoamine distribution in primate brain V. Monoaminergic nuclei: anatomy, pathways and local organization.

  1983cited by this paper
• A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1983cited by this paper
• Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

  1983cited by this paper
• Monoamine distribution in primate brain. V. Monoaminergic nuclei: anatomy, pathways, and local organization.

  1982cited by this paper
• Correspondence of melanin-pigmented neurons in human brain with A1-A14 catecholamine cell groups.

  1982cited by this paper
• Histochemical mapping of catecholaminergic neurons and their ascending fiber pathways in the rhesus monkey brain.

  1982cited by this paper
• Brainstem innervation of prefrontal and anterior cingulate cortex in the rhesus monkey revealed by retrograde transport of HRP

  1982cited by this paper
• The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat.

  1982cited by this paper
• Organization of the amygdalopetal projections from modality‐specific cortical association areas in the monkey

  1980cited by this paper
• Computerized densitometry and color coding of [14C] deoxyglucose autoradiographs

  1980cited by this paper
• Efferent connections of the substantia nigra and ventral tegmental area in the rat.

  1979cited by this paper
• A brainstem atlas of catecholaminergic neurons and serotonergic perikarya in a pygmy primate (Cebuella pygmaea)

  1978cited by this paper
• Juvenile parkinsonism: A patient with possible primary striatal dysfunction

  1978cited by this paper
• FURTHER EVIDENCE FOR THE PRESENCE OF NIGRO-NEOSTRIATAL DOPAMINE NEURONS IN THE RAT.

  1965cited by this paper
• INFLUENCE OF THE SUBSTANTIA NIGRA ON THE CATECHOLAMINE CONTENT OF THE STRIATUM.

  1965cited by this paper
• A Stereotaxic Atlas of the Monkey Brain

  1962cited by this paper

• Quantitative Analysis of Locus Coeruleus Neurons and Thalamic Noradrenergic Axons in a Progressive 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Monkey Model of Parkinson's Disease.

  2026cites this paper
• MicroRNAs and synaptic dysfunction in Parkinson’s disease

  2025cites this paper
• MicroRNAs alteration and unique distribution in the soma and synapses of substantia nigra in Parkinson’s disease

  2025cites this paper
• High-frequency repetitive transcranial magnetic stimulation upregulates BDNF expression and promotes synaptogenesis in mouse models of Parkinson's disease.

  2025cites this paper
• Copper supplementation mitigates Parkinson-like wild-type SOD1 pathology and nigrostriatal degeneration in a novel mouse model

  2025cites this paper
• Selective dopaminergic neurotoxicity modulated by inherent cell-type specific neurobiology.

  2024cites this paper
• LUHMES Cells: Phenotype Refinement and Development of an MPP+-Based Test System for Screening Antiparkinsonian Drugs

  2023cites this paper
• Specific Attenuation of Purinergic Signaling during Bortezomib-Induced Peripheral Neuropathy In Vitro

  2022cites this paper
• Temporal, spatial and molecular pattern of dopaminergic neurodegeneration in the AAV-A53T α-synuclein rat model of Parkinson's disease.

  2022cites this paper
• Specific attenuation of purinergic signaling during bortezomib-induced peripheral neuropathy

  2022cites this paper
• Cortical Serotonergic and Catecholaminergic Denervation in MPTP-Treated Parkinsonian Monkeys.

  2021cites this paper
• Comparative Ultrastructural Analysis of Thalamocortical Innervation of the Primary Motor Cortex and Supplementary Motor Area in Control and MPTP-Treated Parkinsonian Monkeys.

  2021cites this paper
• Experimental deep brain stimulation in rodent models of movement disorders.

  2021cites this paper
• Cholinergic deficits and galaninergic hyperinnervation of the nucleus basalis of Meynert in Alzheimer’s disease and Lewy body disorders

  2020cites this paper
• The kainate receptor antagonist UBP310 but not single deletion of GluK1, GluK2, or GluK3 subunits, inhibits MPTP-induced degeneration in the mouse midbrain.

  2020cites this paper
• Neurotheranostics as personalized medicines.

  2019cites this paper
• Thalamic degeneration in MPTP-treated Parkinsonian monkeys: impact upon glutamatergic innervation of striatal cholinergic interneurons

  2019cites this paper
• Neuromelanin modulates heterocyclic aromatic amine-induced dopaminergic neurotoxicity.

  2019cites this paper
• Neuroprotective role of kolaviron in striatal redo-inflammation associated with rotenone model of Parkinson's disease.

  2019cites this paper
• Microdevices for Isolating Single Axons for the Study of Axonal Transport in Dopaminergic Neurons

  2019cites this paper
• Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson’s disease

  2018cites this paper
• Peripheral Administration of Tetanus Toxin Hc Fragment Prevents MPP+ Toxicity In Vivo

  2018cites this paper
• Decreased Mcl-1 protein level in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice.

  2018cites this paper
• Mitochondrial dysfunction within the synapses of substantia nigra neurons in Parkinson’s disease

  2018cites this paper
• The Complex Genetics behind Neurodegeneration and Susceptibility to Parkinson’s disease

  2017cites this paper
• Characterization of FBXO7 (PARK15) knockout mice modeling Parkinsonian-Pyramidal Syndrome

  2017cites this paper
• LRRK 2 G 2019 S-induced mitochondrial DNA damage is LRRK 2 kinase dependent and inhibition restores mtDNA integrity in Parkinson ’ s disease

  2017cites this paper
• LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease

  2017cites this paper
• Evaluation of selected dye compounds as inhibitors of monoamine oxidase

  2017cites this paper
• Cell surface GRP78 and its interactions with CDNF and MANF

  2016cites this paper
• MiR-133b ameliorates axon degeneration induced by MPP(+) via targeting RhoA.

  2016cites this paper
• Chronic models of the preclinical and early clinical stages of Parkinson’s disease in mice

  2016cites this paper
• Microdevices for Isolating Single Axons for the Study of Axonal Transport in Dopaminergic Neurons

  2016cites this paper
• Metalloproteinase-9 contributes to inflammatory glia activation and nigro-striatal pathway degeneration in both mouse and monkey models of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism

  2015cites this paper
• L'impact de la surexpression de pré-enképhaline striatale sur la dyskinésie induite par la L-DOPA dans la maladie de Parkinson

  2015cites this paper
• Role of the Akt/GSK-3β/CRMP-2 pathway in axon degeneration of dopaminergic neurons resulting from MPP+ toxicity.

  2015cites this paper
• Modulation of the expression and function of dopaminergic presynaptic proteins by the statins : Potential implication for the therapeutic intervention in Parkinson’s disease.

  2015cites this paper
• MPTP Neurotoxicity: Actions, Mechanisms, and Animal Modelling of Parkinson’s Disease

  2014cites this paper
• The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia

  2014cites this paper
• A viral peptide that targets mitochondria protects against neuronal degeneration in models of Parkinson’s disease

  2014cites this paper
• Causes and Consequences of Degeneration of the Dorsal Motor Nucleus of the Vagus Nerve in Parkinson's Disease

  2014cites this paper
• Axon degeneration and PGC-1α-mediated protection in a zebrafish model of α-synuclein toxicity

  2014cites this paper
• Time course of dopamine neuron loss and glial response in the 6‐OHDA striatal mouse model of Parkinson's disease

  2014cites this paper
• RUNNING TITLE: α-synuclein toxicity in zebrafish

  2014cites this paper
• Neuronal loss in the caudal intralaminar thalamic nuclei in a primate model of Parkinson’s disease

  2013cites this paper
• MALDI Mass Spectrometry Imaging of 1-Methyl-4-phenylpyridinium (MPP+) in Mouse Brain

  2013cites this paper
• The Effects of Locus Coeruleus and Norepinephrine in Methamphetamine Toxicity

  2013cites this paper
• In Vivo Evidence of Increased nNOS Activity in Acute MPTP Neurotoxicity: A Functional Pharmacological MRI Study

  2013cites this paper
• Reduced noradrenaline, but not dopamine and serotonin in motor thalamus of the MPTP primate: relation to severity of Parkinsonism

  2013cites this paper
• Axon degeneration in Parkinson's disease.

  2013cites this paper
• Microdevices for Isolating Single Axons for the Study of Axonal Transport in Dopaminergic Neurons

  2013cites this paper
• Evidence of oligodendrogliosis in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced Parkinsonism

  2013cites this paper
• No Differential Regulation of Dopamine Transporter (DAT) and Vesicular Monoamine Transporter 2 (VMAT2) Binding in a Primate Model of Parkinson Disease

  2012cites this paper
• Le rôle de la protéine beta-arrestine 2 dans les effets neuroprotecteurs du lithium

  2012cites this paper
• Evidence of oligodendrogliosis in MPTP-induced Parkinsonism 1

  2012cites this paper
• Pale Neurites, Premature α‐Synuclein Aggregates with Centripetal Extension from Axon Collaterals

  2012cites this paper
• Development of a dual-hit model of Parkinson's disease by combining environmental and genetic risk factors

  2012cites this paper
• Low nigrostriatal reserve for motor parkinsonism in nonhuman primates.

  2012cites this paper
• Does Mitochondrial DNA Play a Role in Parkinson's Disease? A Review of Cybrid and Other Supportive Evidence

  2012cites this paper
• Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson’s disease

  2012cites this paper
• Evidence of oligodendrogliosis in 1-methyl-4-phenyl-1 , 2 , 3 , 6-tetrahydropyridine ( MPTP )-induced Parkinsonism

  2012cites this paper
• The Antioxidative Effect of Electro-Acupuncture in a Mouse Model of Parkinson's Disease

  2011cites this paper
• Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

  2011cites this paper
• The design, synthesis and evaluation of aminocaffeine derivatives as inhibitors of monoamine oxidase B

  2011cites this paper
• Loss of striatal dopaminergic terminals during the early stage in response to MPTP injection in C57BL/6 mice.

  2011cites this paper
• Modeling of presymptomatic and symptomatic stages of parkinsonism in mice.

  2011cites this paper
• Mechanisms of Observed Neuroprotection of Dopaminergic Neurons in Wallerian Degeneration Slow (WldS) Mice

  2011cites this paper
• Chronic Caffeine Consumption Prevents Memory Disturbance in Different Animal Models of Memory Decline

  2010influential citation
• (18)F-FECNT: validation as PET dopamine transporter ligand in parkinsonism.

  2010cites this paper
• Substance abuse and movement disorders

  2010cites this paper
• F-FECNT : Validation as PET dopamine transporter ligand in parkinsonism

  2010cites this paper
• GSH-DA interactions: relevance to cell vulnerability in Parkinson's disease

  2010cites this paper
• Kinetics of Microglial Activation and Degeneration of Dopamine-Containing Neurons in a Rat Model of Parkinson Disease Induced by 6-Hydroxydopamine

  2009cites this paper
• Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease.

  2009cites this paper
• Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys.

  2009cites this paper
• Zebrafish as a model of Parkinson's disease

  2009cites this paper
• Proteomics in human Parkinson's disease research.

  2009cites this paper
• Striatal Dopaminergic Denervation and Spine Loss in MPTP-Treated Monkeys

  2009cites this paper
• Neuroprotection by adenosine receptors in aged rats - role of neuroinflammation

  2009cites this paper
• Modification upon aging of the density of presynaptic modulation systems in the hippocampus.

  2009cites this paper
• Genetic or pharmacological blockade of noradrenaline synthesis enhances the neurochemical, behavioral, and neurotoxic effects of methamphetamine

  2008cites this paper
• Intrastriatal injection of colchicine induces striatonigral degeneration in mice

  2008cites this paper
• Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum.

  2008cites this paper
• Bak Foong protects dopaminergic neurons against MPTP‐induced neurotoxicity by its anti‐apoptotic activity

  2008cites this paper
• Visualization of monoaminergic neurons and neurotoxicity of MPTP in live transgenic zebrafish.

  2008cites this paper
• Dissociated mesencephalic cultures: A research tool to model dopaminergic cell death in parkinson's disease

  2008cites this paper
• 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C

  2007cites this paper
• Differential effects of dopamine melanin on norharman-induced toxicity in PC12 cells

  2007cites this paper
• Blockade of adenosine A(2A) receptors prevents staurosporine-induced apoptosis of rat hippocampal neurons.

  2007influential citation
• Age‐related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease

  2006cites this paper
• Ablation of the Inflammatory Enzyme Myeloperoxidase Mitigates Features of Parkinson's Disease in Mice

  2005cites this paper
• Torsin-Mediated Protection from Cellular Stress in the Dopaminergic Neurons of Caenorhabditis elegans

  2005cites this paper
• Short and long-term changes in cerebral [14C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity

  2005cites this paper
• Influence of paraquat on dopaminergic transporter in the rat brain.

  2005cites this paper
• Method of treating parkinson's disease in humans by direct infusion of glial cell-line derived neurotrophic factor into the zona incerta

  2005cites this paper
• JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease.

  2004cites this paper
• Long-term retention of neurotoxic β-carbolines in brain neuromelanin

  2004cites this paper
• Long-term retention of neurotoxic beta-carbolines in brain neuromelanin.

  2004cites this paper
• Reduced MPTP toxicity in noradrenaline transporter knockout mice

  2004cites this paper
• In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6‐hydroxydopamine‐lesioned rats

  2004cites this paper